Results 121 to 130 of about 985,459 (298)

Pancreatic secretory trypsin inhibitor stimulates the growth of rat pancreatic carcinoma cells [PDF]

, 1990
Pancreatic secretory trypsin inhibitor was examined for growth-promoting activity on five cell lines using standard cell culture techniques. One cell line, AR4-2J, derived from a rat pancreatic acinar cell carcinoma, responded with significantly ...
Curry, B J, Calam, J, Freeman, T C, Woodburn, J R   +3 more
core  

Modelling stem cell differentiation related processes—A practical overview for biologists

FEBS Letters, EarlyView.
Stem cell differentiation is complex and difficult to control experimentally. This review introduces suitable computational modelling approaches that can support stem cell research, from mechanistic ODE and abstract models to multiscale and deep learning methods.
Ricco Zeegelaar, Xinqi Yan, Lucas F. Jansen Klomp, Stefano Schivo, Janine N. Post   +4 more
wiley   +1 more source

Selective JAK-Inhibitors in Spondyloarthritis

Mediterranean Journal of Rheumatology
As our research interest and knowledge increases in the field of Spondyloarthritis, new aspects also emerge as regards to their therapeutic approach. JAK inhibitors (JAKi) are a relatively new treatment option, aiming molecules in the JAK-STAT pathway, which has a leading role in the pathophysiology of both Psoriatic Arthritis and Axial ...
Vassilakis, Konstantinos D., Magiouf, Konstantina, Siebert, Stefan, Fragoulis, George E.   +3 more
openaire   +3 more sources

Tofacitinib for Pityriasis Rubra Pilaris: A Case Report

Clinical, Cosmetic and Investigational Dermatology
Hongyan Tan, Bin Zhang, Xiawei Kang, Lvyao Wang, Xiao Qiu, Xiangyu Hu Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, 400011, People’s Republic of ChinaCorrespondence: Xiangyu Hu, Email 369930758@qq.comPurpose ...
Tan H, Zhang B, Kang X, Wang L, Qiu X, Hu X   +5 more
doaj  

ABL kinase‐dependent phosphorylation of SH proteins promotes their direct interaction with CRK family SH2 domains

FEBS Letters, EarlyView.
CT10 regulator of kinase (CRK) and CRK‐Like (CRKL) are signaling adaptors driving cell adhesion, motility, differentiation, and proliferation. SH2‐domain containing (SH) proteins are enriched in YXXP motifs which when phosphorylated create preferred binding sites for CRK family SH2 domains.
Phoebe M. Cousens, Brendan W. Chandler, Anna M. Schmoker, Jaye L. Weinert, Charlotte A. Kearns, Warren T. Yacawych, Amila Šemić, Alicia M. Ebert, Bryan A. Ballif   +8 more
wiley   +1 more source

JAK Inhibitor Clinical Response in Polyarthritis: Case Report

Acta Clinica Croatica, 2015
The heterogeneity of rheumatoid arthritis (RA) presentation and molecular signature of RA subclasses in patients with early changes of small peripheral joints still remains a challenging problem.
Asja Stipić-Marković, Iva Ferček, Marta Čubela, Marinko Artuković, Ksenija Maštrović Radončič, Liborija Lugović-Mihić   +5 more
doaj  

Efficacy of Oral Tofacitinib in Moderate-to-Severe Pediatric Atopic Dermatitis: A Case Series

Indian Journal of Paediatric Dermatology
Atopic dermatitis (AD) is a chronic skin disease most commonly affecting children. The pathophysiology is thought to be influenced by the JAK-STAT signalling system. There are very few studies showing the efficacy of JAK-STAT inhibitors in AD.
Archita Bhattacharya, Abhipsa Samal, Bikash Ranjan Kar, Manoj Kumar Nayak, Nibedita Dixit, Liza Mohapatra   +5 more
doaj   +1 more source

Reconstructing enzyme evolution by protein engineering

FEBS Letters, EarlyView.
Natural enzyme evolution can be retraced by protein engineering methods such as directed evolution, rational design, and ancestral sequence reconstruction. These approaches reveal how enzymes emerged from ligand‐binding scaffolds, developed varying substrate preferences, formed oligomeric complexes, adapted to environmental changes, and evolved novel ...
Lukas Drexler, Markus R. Busch, Reinhard Sterner   +2 more
wiley   +1 more source

Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro [PDF]

, 2012
Lyons, John, Holyoake, Tessa L., Jorgensen, Heather, Shah, Mohsin, Gallipoli, Paolo   +4 more
core   +1 more source

RuBi-Ruxolitinib: a photoreleasable antitumor JAK inhibitor

We describe the synthesis and biological testing of ruthenium-bipyridine ruxolitinib (RuBiRuxo), a photo-releasable form of ruxolitinib, a JAK inhibitor used as an antitumoral agent in cutaneous T-cell lymphomas (CTCL).
Etchenique, Roberto, Palomero, Teresa, Rafic, Estefanía Constanza, Ma, Cindy, Shih, Bobby B., Etchenique, Roberto Argentino, Miller, Hannah, Yuste, Rafael, Rafic, Estefania   +8 more
core   +2 more sources